Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 257 results for radiotherapy

  1. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  2. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

  3. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  4. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

  5. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)

    This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.

  6. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

  7. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

  8. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued Reference number: GID-TA10443

  9. The MAGEC system for spinal lengthening in children with scoliosis (MT169)

    Discontinued Reference number: GID-MT544

  10. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

  11. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.

  12. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

  13. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

  14. ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)

    NICE has developed a medtech innovation briefing (MIB) on ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment

  15. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued Reference number: GID-MT536